Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 7;10(24):5732.
doi: 10.3390/jcm10245732.

Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan

Yukari Okubo  1 , Ann Chuo Tang  2 , Sachie Inoue  3 , Hitoe Torisu-Itakura  4 , Mamitaro Ohtsuki  5
Affiliations

Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan

Yukari Okubo et al. J Clin Med. .

Abstract

Background: Previously, our cross-sectional observational study in Japan revealed high (68%) discordance within treatment goals between psoriasis patients and their physicians.

Objective: This secondary analysis aimed to determine whether patient and physician users of biologics have higher treatment goals than users of non-biologics.

Methods: A survey for both patients and physicians on background characteristics, disease severity, treatment goals, treatment satisfaction, and health-related quality of life was conducted at 54 sites. Association between treatment goals and biologic/non-biologic users was assessed using ordinal logistic regression models.

Results: In total, 449 patient-physician pairs agreed to participate; 425 completed the survey and were analyzed. More biologic users than non-biologic users reported complete clearance (Psoriasis Area and Severity Index 100) as a treatment goal (patient-reported: 23.6% vs. 16.1%; physician-reported: 26.9% vs. 2.2%). Biologic users were significantly associated with higher treatment goals than non-biologic users (patient-reported: 1.8 (1.15-2.87) (odds ratio (9 5% CI)), p = 0.01; physician-reported: 11.0 (5.72-21.01), p < 0.01). Among biologic users, higher treatment goals were associated with higher treatment satisfaction (patient- and physician-rated); lower treatment goals were associated with back lesions and increasing patient age (patient-rated) and higher disease severity (physician-rated).

Conclusion: Use of biologics among patients with psoriasis was associated with higher treatment goals. Further use of biologics contributed to treatment satisfaction. Appropriate treatment goals that are shared among patients and their physicians may improve treatment outcomes.

Keywords: Japan; biologics; cross-sectional studies; health care surveys; psoriasis; treatment goal.

PubMed Disclaimer

Conflict of interest statement

Y. Okubo has been a consultant, scientific advisor and/or investigator for Eli Lilly K.K., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Maruho Co. Ltd., Celgene K.K., Janssen Pharmaceutical K.K., AbbVie GK, Eisai Co. Ltd., Torii Pharmaceutical Co. Ltd., Leo Pharma A/S, MSD K.K., Boehringer Ingelheim Japan, Inc., Novartis AG, Taiho Pharmaceutical CO., Ltd., and Bristol-Meiers Squibb Company. M. Ohtsuki has been paid as a consultant to AbbVie GK, Boehringer-Ingelheim Japan, Inc., Celgene K.K., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Kyowa Hakko Kirin Co. Ltd., LEO Pharma A/S, Eli Lilly and Company, Maruho Co. Ltd., Novartis AG, Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Torii Pharmaceutical Co. Ltd., Taiho Pharmaceutical CO., Ltd., Amgen Inc., Sun Pharma Japan Ltd., UCB Japan Co. Ltd., and Bristol-Myers Squibb Company. S. Inoue is an employee of CRECON Medical Assessment Inc.; CRECON Medical Assessment Inc. was paid to conduct the analyses for this report. A.C. Tang is an employee of Eli Lilly K.K. Japan. H. Torisu-Itakura is an employee of Eli Lilly K.K. Japan and is an Eli Lilly stock holder.

Figures

Figure 1
Figure 1
Patient- and physician-reported treatment goals. Goal 1 = complete clearance (Psoriasis Area and Severity Index (PASI) 100) [21], Goal 2 = almost complete clearance (PASI 90 to <100), Goal 3 = complete clearance at specific sites (nails, head, genitals, other), Goal 4 = improvement from previous treatment, but without “complete” or “almost complete clearance”, Goal 5 = relief from itchiness, Goal 6 = other goals, and Goal 7 = no particular goal set. (a) A larger number of patient (23.6% vs. 16.1%) and (b) physician (26.0% vs. 2.2%) among biologic users had higher treatment goals of achieving complete clearance.
See this image and copyright information in PMC

References

    1. Kubota K., Kamijima Y., Sato T., Ooba N., Koide D., Iizuka H., Nakagawa H. Epidemiology of psoriasis and palmoplantar pustulosis: A nationwide study using the Japanese national claims database. BMJ Open. 2015;5:e006450. doi: 10.1136/bmjopen-2014-006450. - DOI - PMC - PubMed
    1. Ito T., Takahashi H., Kawada A., Iizuka H., Nakagawa H. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J. Dermatol. 2018;45:293–301. doi: 10.1111/1346-8138.14105. - DOI - PubMed
    1. Hirabe M., Hasegawa T., Fujishiro Y., Kigawa M., Fukuchi O., Nakagawa H. Factors associated with quality of life among patients with psoriasis. Comparison between psoriasis-specific QOL measures and generic QOL measures. Nihon Koshu Eisei Zasshi. 2008;55:65–74. - PubMed
    1. Mabuchi T., Yamaoka H., Kojima T., Ikoma N., Akasaka E., Ozawa A. Psoriasis affects patient’s quality of life more seriously in female than in male in Japan. Tokai J. Exp. Clin. Med. 2012;37:84–88. - PubMed
    1. Okubo Y., Arai K., Fujiwara S., Amaya M., Tsuboi R. Assessment of the quality of life of patients with psoriasis using Skindex-16 and GHQ-28. Jpn. J. Dermatol. 2007;117:2495–2505.

LinkOut - more resources